Szilberhorn László, Zelei Tamás, Vellekoop Heleen, Huygens Simone, Versteegh Matthijs, Mölken Maureen Rutten-van, Koleva-Kolarova Rositsa, Tsiachristas Apostolos, Wordsworth Sarah, Nagy Balázs
Syreon Research Institute, 1142, Budapest, Hungary.
Institute for Medical Technology Assessment, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.
Per Med. 2023 Jul;20(4):387-399. doi: 10.2217/pme-2023-0017. Epub 2023 Sep 4.
Correct diagnosis of maturity-onset diabetes of the young (MODY), which is often misdiagnosed as Type 1 or 2 diabetes, is important for providing appropriate treatment. A diabetes model was adapted to Hungary, the Netherlands, and the UK to analyse the cost-effectiveness and budget impact of different screening strategies for MODY with 20 years time horizon. Compared with no screening, screening with the MODY calculator then genetic testing is considered cost-effective with respect to each country's willingness to pay threshold. The addition of autoantibody testing dominated the no screening strategy. The budget impact of the strategies ranges between 0.001 and 0.025% of annual public healthcare spending. The analysed strategies are considered good value for money with potential cost savings in the long term.
正确诊断青年发病型成年糖尿病（MODY）很重要，因为它常常被误诊为1型或2型糖尿病，而正确诊断有助于提供适当的治疗。一种糖尿病模型被应用于匈牙利、荷兰和英国，以分析不同的MODY筛查策略在20年时间范围内的成本效益和预算影响。与不进行筛查相比，使用MODY计算器然后进行基因检测的筛查方式，就每个国家的支付意愿阈值而言，被认为具有成本效益。添加自身抗体检测优于不筛查策略。这些策略的预算影响在年度公共医疗支出的0.001%至0.025%之间。所分析的策略被认为性价比高，从长远来看可能会节省成本。
